

Opdivo® (nivolumab) and Yervoy® (ipilimumab) – New indication

- On April 16, 2017, [Bristol-Myers Squibb announced](#) the FDA approval of [Opdivo \(nivolumab\)](#) plus [Yervoy \(ipilimumab\)](#) for the combination treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC).
 - Opdivo was previously approved as a single agent for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.
- Opdivo is also indicated for the treatment of unresectable or metastatic melanoma, adjuvant treatment of melanoma, metastatic non-small cell lung cancer, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, and hepatocellular carcinoma.
- Yervoy is also indicated for the treatment of unresectable or metastatic melanoma and for adjuvant treatment of melanoma.
- According to the [American Cancer Society](#), approximately 63,340 new cases of RCC will occur in 2018. Of those with advanced RCC, 75% – 80% have one or more risk factors and are considered intermediate or poor risk patients.
- The efficacy of Opdivo in combination with Yervoy for the new indication is based on a [clinical study](#) of 847 patients with intermediate or poor risk, previously untreated advanced RCC. Patients were randomized to Opdivo plus Yervoy followed by Opdivo monotherapy vs. [Sutent® \(sunitinib\)](#). The co-primary endpoints were overall survival (OS), objective response rate (ORR), and progression-free survival (PFS).
 - Opdivo plus Yervoy reduced the risk of death by 37% versus sunitinib (HR = 0.63, [99.8% CI: 0.44 to 0.89]; $p < 0.0001$).
 - Opdivo plus Yervoy was associated with a 41.6% ORR vs. 26.5% for sunitinib ($p < 0.0001$).
 - However, PFS did not reach statistical significance for Opdivo plus Yervoy vs. sunitinib (11.6 months vs. 8.4 months) at alpha level of 0.009.
- Yervoy carries a boxed warning regarding the risk of immune-mediated adverse reactions.
- In RCC patients, the most common adverse reactions with Opdivo plus Yervoy use were fatigue, rash, diarrhea, musculoskeletal pain, pruritus, nausea, cough, pyrexia, arthralgia, and decreased appetite.
- In patients with intermediate or poor risk, previously untreated advanced RCC, the recommended dose is Opdivo 3 mg/kg administered as an intravenous (IV) infusion, followed by Yervoy 1 mg/kg administered as an IV infusion on the same day, every 3 weeks for 4 doses.
 - After completing 4 doses of the combination, administer Opdivo as a single agent, either 240 mg every 2 weeks or 480 mg every 4 weeks as an IV infusion until disease progression or unacceptable toxicity.

- Refer to the Opdivo and Yervoy drug labels for dosing information for all other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.